"","drug","drug_drugbank_standard","drug_pubchem","biomarker","biomarker_ensembl_standard","biomarker_type","biomarker_direction","biomarker_relations","biomarker_description","disease","diseases_id_standard","drug_targets","QC","curator","raw_table","source","source_id","record_id"
"1","ABACAVIR","DB01048","441300","HLA-B","ENSG00000234745","polymorphism",NA,NA,"HLA-B POLYMORPHISM NA","AIDS","EFO_0000765","NRTI","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG594659457"
"2","ABEMACICLIB","DB12001","46220502","ESR, ERBB2","ENSG00000091831, ENSG00000141736","protein expression, protein expression & amplification","positive, negative","AND","ESR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","(HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","CDK4; CDK6","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1498962895"
"4","AFATINIB","DB08916","10184653","EGFR","ENSG00000146648","mutation",NA,NA,"EGFR MUTATION NA","LUNG CANCER","MONDO_0008903","EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2; ErbB4","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1064188334"
"5","ALECTINIB","DB11363","49806720","ALK","ENSG00000171094","protein expression",NA,NA,"ALK PROTEIN EXPRESSION NA","NON-SMALL CELL LUNG CANCER THAT HAS SPREAD TO OTHER PARTS OF THE BODY","EFO_0003060","ALK; ALK (F1174L); ALK (R1275Q); INSR; VEGFR2 (KDR)","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1932775397"
"6","ALPELISIB","DB12015","56649450","ESR, ERBB2, PIK3CA","ENSG00000091831, ENSG00000141736, ENSG00000121879","protein expression, protein expression & amplification,  mutation","positive, negative,positive","AND,AND","ESR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND PIK3CA MUTATION POSITIVE","ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","PI3Kα; p110α; p110γ","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-955586545"
"7","AMIFAMPRIDINE","DB11640","9920716","NAT2","ENSG00000156006","polymorphism",NA,NA,"NAT2 POLYMORPHISM NA","LAMBERT-EATON MYASTHENIA SYNDROME IN ADULTS","MONDO_0023370","potassium channel","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1386474016"
"8","AMIFAMPRIDINE PHOSPHATE",NA,"9920716","NAT2","ENSG00000156006","polymorphism",NA,NA,"NAT2 POLYMORPHISM NA","LAMBERT-EATON SYNDROME","MONDO_0023370","potassium channel","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1029442076"
"9","AMITRIPTYLINE","DB00321","11065","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","DEPRESSION","EFO_0003761","5-HT; 5-HT2; 5-HT4; Norepinephrine receptor; σ1","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1233009142"
"10","AMOXAPINE","DB00543","2170","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","DEPRESSION","EFO_0003761","GlyT1b; GlyT2a","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG979588562"
"11","AMPHETAMINE","DB00182","3007","CYP2D7","ENSG00000205702","polymorphism",NA,NA,"CYP2D7 POLYMORPHISM NA","ATTENTION DEFICIT HYPERACTIVITY DISORDER,OBESITY","EFO_0001073",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG2008815520"
"13","ARFORMOTEROL","DB01274","3083544","UGT1A1, CYP2D6","ENSG00000241635, ENSG00000100197","polymorphism, polymorphism","positive, positive","AND/OR","UGT1A1 POLYMORPHISM POSITIVE AND/OR CYP2D6 POLYMORPHISM POSITIVE","CHRONIC OBSTRUCTIVE PULMONARY DISEASE","EFO_0000341","β2-adrenergic receptor","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG445115987"
"14","ARIPIPRAZOLE   LAUROXIL",NA,"49831411","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","SCHIZOPHRENIA AND BIPOLAR DISORDER,MAJOR DEPRESSION,TOURETTE'S DISEASE OR AUTISM","EFO_0000289","5-HT2A","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-493957746"
"15","ARSENIC TRIOXIDE","DB01169",NA,"PML-RARA","ENSG00000133246","translocation",NA,NA,"PML-RARA TRANSLOCATION NA","BLOOD AND BONE MARROW CANCERS","MONDO_0021138","HK2(Hexokinase 2)","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1476585244"
"16","ARTICAINE, EPINEPHRINE","DB09009,DB00668","32169, 5816","G6PD","ENSG00000160211","protein expression",NA,NA,"G6PD PROTEIN EXPRESSION NA","ANESTHESIOLOGY,BEFORE DENTAL CARE TO NUMB THE AREA","OTAR_0000018",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1745727063"
"17","ATEZOLIZUMAB","DB11595",NA,"CD274","ENSG00000120217","protein expression",NA,NA,"CD274 PROTEIN EXPRESSION NA","BREAST BLADDER AND URINARY TRACT CANCERS, NON-SMALL CELL LUNG CANCER.","MONDO_0007254","hPD-L1","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1850603683"
"18","ATEZOLIZUMAB","DB11595",NA,"CD274, Gene Signature
(T-effector)","ENSG00000120217, NA","protein expression, others","positive, positive","AND","CD274 PROTEIN EXPRESSION POSITIVE AND GENE SIGNATURE
(T-EFFECTOR) OTHERS POSITIVE","METASTATIC CHEMOTHERAPY-NAIVE NON-SQUAMOUS NSCLC","EFO_0000707","hPD-L1","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG875467658"
"19","ATEZOLIZUMAB","DB11595",NA,"CD274, EGFR, ALK","ENSG00000120217, ENSG00000146648, ENSG00000171094","protein expression, mutation, mutation","positive, negative, negative","AND, AND","CD274 PROTEIN EXPRESSION POSITIVE AND EGFR MUTATION NEGATIVE AND ALK MUTATION NEGATIVE","NON-SMALL CELL LUNG CANCER.","EFO_0003060",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1616970176"
"20","ATOMOXETINE","DB00289","54840","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","HYPERACTIVE ATTENTION DEFICIT","EFO_0003888","5-HT; DA transporter; Norepinephrine (NE) transporter","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-292801829"
"22","AVATROMBOPAG","DB11995","9852519","F2, F5, PROC, PROS1, SERPINC1, CYP2C9","ENSG00000180210, ENSG00000198734, ENSG00000115718, ENSG00000184500, ENSG00000117601, ENSG00000138109","polymorphism, polymorphism, polymorphism, polymorphism, polymorphism, polymorphism","negative,negative,negative, negative,negative,negative","OR, OR, OR, OR, OR","F2 POLYMORPHISM NEGATIVE OR F5 POLYMORPHISM NEGATIVE OR PROC POLYMORPHISM NEGATIVE OR PROS1 POLYMORPHISM NEGATIVE OR SERPINC1 POLYMORPHISM NEGATIVE OR CYP2C9 POLYMORPHISM NEGATIVE","THROMBOTIC","Orphanet_183589","TPOreceptor","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG719702881"
"23","AVELUMAB","DB11945",NA,"CD274","ENSG00000120217","protein expression",NA,NA,"CD274 PROTEIN EXPRESSION NA","MERCKLE CELL CARCINOMA","EFO_0000707","PD-L1","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1188758294"
"24","AZATHIOPRINE","DB00993","2265","TPMT, NUDT15","ENSG00000137364, ENSG00000136159","polymorphism, polymorphism","negative, negative","AND/OR","TPMT POLYMORPHISM NEGATIVE AND/OR NUDT15 POLYMORPHISM NEGATIVE","AUTOIMMUNE DISEASES","EFO_1000870","HGPRT; Rac1;","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1048595055"
"25","BELINOSTAT","DB05015","6918638","UGT1A1","ENSG00000241635","polymorphism",NA,NA,"UGT1A1 POLYMORPHISM NA","T CELL LYMPHOMA","EFO_0002913","HDAC","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG2059480590"
"26","BINIMETINIB","DB11967","10288191","BRAF","ENSG00000157764","mutation",NA,NA,"BRAF MUTATION NA","MELANOMA","EFO_0000756","MEK1&2","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG736314554"
"28","BOCEPREVIR","DB08873","10324367","IFNL3
","ENSG00000197110","protein expression",NA,NA,"IFNL3 PROTEIN EXPRESSION NA","HEPATITIS C INFECTION","EFO_0004220","HCV NS3 protease","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-378943012"
"30","BRENTUXIMAB VEDOTIN","DB08870",NA,"ALK","ENSG00000171094","mutation",NA,NA,"ALK MUTATION NA","CLASSICAL HODGKIN LYMPHOMA,ANAPLASTIC LARGE CELL LYMPHOMA","EFO_0000574","ADCs Linker","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-771556728"
"31","BRENTUXIMAB VEDOTIN","DB08870",NA,"TNFRSF8","ENSG00000120949","protein expression",NA,NA,"TNFRSF8 PROTEIN EXPRESSION NA","CLASSICAL HODGKIN LYMPHOMA,ANAPLASTIC LARGE CELL LYMPHOMA","EFO_0000574","ADCs Linker","pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1173989673"
"32","BREXPIPRAZOLE","DB09128","11978813","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","SCHIZOPHRENIA,SEVERE DEPRESSION,ALZHEIMER'S DISEASE","EFO_0000249",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG829815143"
"33","BRIGATINIB","DB12267","68165256","ALK","ENSG00000171094","mutation",NA,NA,"ALK MUTATION NA","NON-SMALL CELL LUNG CANCER THAT HAS SPREAD TO OTHER PARTS OF THE BODY","EFO_0003060",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1437695799"
"34","BRIVARACETAM","DB05541","9837243","CYP2C19","ENSG00000165841","polymorphism",NA,NA,"CYP2C19 POLYMORPHISM NA","EPILEPSY","EFO_0000474",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG282615554"
"35","CABOZANTINIB","DB08875","25102846","RET","ENSG00000165731","genetic others",NA,NA,"RET GENETIC OTHERS NA","NON-SMALL-CELL LUNG CANCER","EFO_0003060",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG816316872"
"36","CAPECITABINE","DB01101","60953","DPYD","ENSG00000188641","mutation",NA,NA,"DPYD MUTATION NA","COLORECTAL CANCER,REAST CANCER","EFO_0005842",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1533469514"
"37","CARBAMAZEPINE","DB00564","2554","HLA-B, HLA-A","ENSG00000234745, ENSG00000206503","polymorphism, polymorphism","negative, negative","AND/OR","HLA-B POLYMORPHISM NEGATIVE AND/OR HLA-A POLYMORPHISM NEGATIVE","BRIVARACETAM,EPILEPSY,ANTICONVULSANTS","EFO_0000474",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG205847830"
"38","CARGLUMIC ACID","DB06775","121396","NAGS","ENSG00000161653","protein expression",NA,NA,"NAGS PROTEIN EXPRESSION NA","INBORN ERRORS OF METABOLISM,HIGH AMMONIA LEVELS","Orphanet_68367",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG541509081"
"39","CARIPRAZINE","DB06016","11154555","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","SCHIZOPHRENIA,BIPOLAR I DISORDER","EFO_0000289",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1069940068"
"40","CARISOPRODOL","DB00395","2576","CYP2C19","ENSG00000165841","polymorphism",NA,NA,"CYP2C19 POLYMORPHISM NA","SKELETAL MUSCLE DISEAS","Orphanet_206634",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1900108140"
"41","CARVEDILOL","DB01136","2585","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","HEART FAILURE,HIGH BLOOD PRESSURE,HEART DISEASE","EFO_0003777",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1557071629"
"42","CELECOXIB","DB00482","2662","CYP2C9","ENSG00000138109","polymorphism",NA,NA,"CYP2C9 POLYMORPHISM NA","ARTHRITIS, ANKYLOSIS AND MENSTRUAL PAIN,RHEUMATOID ARTHRITIS","EFO_0000685",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG900270885"
"43","CEFTRIAXONE","DB01212","5479530","G6PD","ENSG00000160211","polymorphism",NA,NA,"G6PD POLYMORPHISM NA","TREAT OR PREVENT BACTERIAL INFECTIONS","EFO_0000771",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG570155103"
"44","CERITINIB","DB09063","57379345","ALK","ENSG00000171094","mutation",NA,NA,"ALK MUTATION NA","LUNG CANCER","MONDO_0008903",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-413895656"
"45","CERLIPONASE ALFA","DB13173",NA,"TPP1","ENSG00000166340","mutation",NA,NA,"TPP1 MUTATION NA","TYPE 2 DISEASE OF CEROID LIPOFUSCINOSIS (CLN2)","EFO_1000051",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-2121880163"
"46","CETUXIMAB","DB00002","136170999","RAS","ENSG00000133703","mutation",NA,NA,"RAS MUTATION NA","CANCER OF THE HEAD AND NECK","EFO_0006859",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1928793512"
"47","CRIZANLIZUMAB","DB15271",NA,"HBB","ENSG00000244734","mutation",NA,NA,"HBB MUTATION NA","PEOPLE WITH SICKLE CELL DISEASE","EFO_1000636",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1667727299"
"48","CRIZOTINIB","DB08865","11626560","ROS1","ENSG00000047936","gene fusion",NA,NA,"ROS1 GENE FUSION NA","LUNG CANCER","MONDO_0008903",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1839732767"
"49","DABRAFENIB","DB08912","44516822","RAS","ENSG00000133703","mutation",NA,NA,"RAS MUTATION NA","SKIN CANCER (MELANOMA)","MONDO_0002898",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1229781644"
"50","DENILEUKIN DIFTITOX","DB00004",NA,"IL2RA
","ENSG00000134460","protein expression",NA,NA,"IL2RA PROTEIN EXPRESSION NA","LEUKEMIA","EFO_0000565",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-210842937"
"52","EFAVIRENZ","DB00625","64139","CYP2B6","ENSG00000197408","polymorphism",NA,NA,"CYP2B6 POLYMORPHISM NA","HIV INFECTION","EFO_0000764",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG779147928"
"53","ELAGOLIX","DB11979","24785956","SLCO1B1","ENSG00000134538","protein expression",NA,NA,"SLCO1B1 PROTEIN EXPRESSION NA","MODERATE TO SEVERE PAIN CAUSED BY ENDOMETRIOSIS.","EFO_0003843",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1440571084"
"59","ENASIDENIB","DB13874","89683805","IDH2","ENSG00000182054","mutation",NA,NA,"IDH2 MUTATION NA","ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WITH AN IDH2 MUTATION.","EFO_0000222",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1362059301"
"60","ENFORTUMAB VEDOTIN-EJFV","DB13007",NA,"NECTIN4","ENSG00000143217","protein expression",NA,NA,"NECTIN4 PROTEIN EXPRESSION NA","ADVANCED UROTHELIAL CARCINOMA, BLADDER CANCER","EFO_0009260",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1738472582"
"61","ENTRECTINIB","DB11986","25141092","NTRK","ENSG00000165300","gene fusion",NA,NA,"NTRK GENE FUSION NA","SOLID TUMOR","Orphanet_84",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-622383070"
"62","ERDAFITINIB","DB12147","67462786","FGFR","ENSG00000068078","mutation & gene fusion",NA,NA,"FGFR MUTATION & GENE FUSION NA","UROTHELIAL CARCINOMA","EFO_0008528",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-239734061"
"63","ESCITALOPRAM","DB01175","146571","CYP2C19","ENSG00000165841","polymorphism",NA,NA,"CYP2C19 POLYMORPHISM NA","DEPRESSION","EFO_0003761",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1869766997"
"64","ESTRADIOL, PROGESTERONE","DB00783,DB00396","5757, 5994","SERPINC1","ENSG00000117601","protein overexpression",NA,NA,"SERPINC1 PROTEIN OVEREXPRESSION NA","VASOMOTOR DISEASE","EFO_0003782",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-978387120"
"65","ETEPLIRSEN","DB06014",NA,"DMD","ENSG00000198947","mutation",NA,NA,"DMD MUTATION NA","DUCHENNE MUSCULAR DYSTROPHY","Orphanet_98896",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-998821726"
"66","FLUOROURACIL","DB00544","3385","DPYD","ENSG00000188641","mutation",NA,NA,"DPYD MUTATION NA","SKIN CANCER","MONDO_0002898",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG363506879"
"67","GILTERITINIB","DB12141","49803313","FLT3","ENSG00000122025","mutation",NA,NA,"FLT3 MUTATION NA","MYELOMATOSIS","EFO_0001378",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-23249570"
"70","IMATINIB","DB00619","123596","KIT, FIP1L1-PDGFRA","ENSG00000157404, ENSG00000282278","mutation, gene fusion","negative, positive","AND","KIT MUTATION NEGATIVE AND FIP1L1-PDGFRA GENE FUSION POSITIVE","AGGRESSIVE SYSTEMIC MASTOCYTOSIS","EFO_0000618",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1859447834"
"72","IMATINIB","DB00619","123596","PDGFRB","ENSG00000113721","translocation",NA,NA,"PDGFRB TRANSLOCATION NA","MYELODYSPLASTIC","MONDO_0020077",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1151651722"
"73","IMATINIB","DB00619","123596","FIP1L1-PDGFRA","ENSG00000282278","gene fusion",NA,NA,"FIP1L1-PDGFRA GENE FUSION NA","HYPEREOSINOPHILIC SYNDROME (HES) AND","EFO_0004842",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1147713356"
"74","INDACATEROL","DB05039","9827599","UGT1A1","ENSG00000241635","polymorphism",NA,NA,"UGT1A1 POLYMORPHISM NA","ASTHMA","EFO_0000270",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG166414512"
"75","INOTERSEN","DB14713","121493436","TTR","ENSG00000118271","protein expression",NA,NA,"TTR PROTEIN EXPRESSION NA","FAP(FAMILIAL AMYLOID POLYNEUROPATHY)","EFO_0002945",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-539500812"
"76","IPILIMUMAB","DB06186",NA,"HLA-A","ENSG00000206503","polymorphism",NA,NA,"HLA-A POLYMORPHISM NA","MELANOMA","EFO_0000756",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-848100356"
"77","ISOSORBIDE DINITRATE","DB00883","6883","CYB5R","ENSG00000100243","protein expression",NA,NA,"CYB5R PROTEIN EXPRESSION NA","ANGINA","EFO_0003913",NA,"pass","Ben","FDA-drug_biomarkers-v8_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1476229835"
"78","IVOSIDENIB","DB14568",NA,"IDH1","ENSG00000138413","mutation","positive",NA,"IDH1 MUTATION POSITIVE","LEUKEMIA","EFO_0000565",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG637500005"
"79","LAPATINIB","DB01259",NA,"HLA-DQA1","ENSG00000196735","polymorphism","positive",NA,"HLA-DQA1 POLYMORPHISM POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-726641820"
"80","LAPATINIB","DB01259",NA,"HLA-DRB1","ENSG00000196126","polymorphism","positive",NA,"HLA-DRB1 POLYMORPHISM POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG496745715"
"81","LAROTRECTINIB","DB14723",NA,"NTRK","ENSG00000165300","gene fusion","positive",NA,"NTRK GENE FUSION POSITIVE","ABNORMAL NTRK GENE CAUSES CERTAIN TUMORS","EFO_0000294",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG453634129"
"83","MIDOSTAURIN","DB06595",NA,"NPM1","ENSG00000181163","mutation","positive",NA,"NPM1 MUTATION POSITIVE","ACUTE MYELOID LEUKEMIA,CERTAIN RARE BLOOD DISORDERS, INCLUDING SYSTEMIC MASTOCYTOSIS WITH MAST CELL LEUKEMIA OR OTHER CANCERS AFFECTING THE BLOOD,BONE MARROW, OR LYMPHATIC TISSUE.","EFO_1000068",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG679917283"
"84","MIDOSTAURIN","DB06595",NA,"KIT","ENSG00000157404","mutation","positive",NA,"KIT MUTATION POSITIVE","ACUTE MYELOID LEUKEMIA,CERTAIN RARE BLOOD DISORDERS, INCLUDING SYSTEMIC MASTOCYTOSIS WITH MAST CELL LEUKEMIA OR OTHER CANCERS AFFECTING THE BLOOD,BONE MARROW, OR LYMPHATIC TISSUE.","EFO_1000068",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-49333377"
"85","MIGALASTAT","DB05018",NA,"GLA","ENSG00000242252","mutation","positive",NA,"GLA MUTATION POSITIVE","FABRY DISEASE","Orphanet_324",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1030127933"
"86","MIVACURIUM","DB01226",NA,"BCHE","ENSG00000114200","polymorphism","positive",NA,"BCHE POLYMORPHISM POSITIVE","CALM MUSCLES DURING SURGERY,CALM MUSCLES WHILE ON A BREATHING MACHINE","MONDO_0003939",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-280478680"
"87","MYCOPHENOLIC ACID","DB01024",NA,"HPRT1","ENSG00000165704","protein expression","positive",NA,"HPRT1 PROTEIN EXPRESSION POSITIVE","RGAN REJECTION AFTER A KIDNEY TRANSPLANT","EFO_0003086",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG2104942858"
"88","NUSINERSEN","DB13161",NA,"SMN2","ENSG00000205571","protein expression","positive",NA,"SMN2 PROTEIN EXPRESSION POSITIVE","SPINAL MUSCULAR ATROPHY","EFO_0008525",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1086936591"
"89","OBINUTUZUMAB","DB08935",NA,"MS4A1","ENSG00000156738","protein expression","positive",NA,"MS4A1 PROTEIN EXPRESSION POSITIVE","LEUKEMIA，LYMPHOMA","EFO_0009119",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-558455940"
"90","OLAPARIB","DB09074",NA,"BRCA","ENSG00000012048","mutation","positive",NA,"BRCA MUTATION POSITIVE","OVARIAN CANCER, FALLOPIAN TUBE CANCER, OR PERITONEAL CANCER IN WOMEN WITH A CERTAIN ABNORMAL INHERITED GENE，HER2-NEGATIVE BREAST CANCER，CANCER HAS A SPECIFIC GENETIC MARKER (AN ABNORMAL ""BRCA"" GENE)","EFO_0000311",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG489011798"
"91","OLARATUMAB","DB06043",NA,"PDGFRA","ENSG00000134853","protein silencing","positive",NA,"PDGFRA PROTEIN SILENCING POSITIVE","SOFT TISSUE SARCOMA","EFO_1001968",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1388758583"
"92","PARATHYROID HORMONE","DB05829",NA,"CASR","ENSG00000036828","mutation","positive",NA,"CASR MUTATION POSITIVE","CONTROL LOW BLOOD CALCIUM LEVELS IN PEOPLE WHO HAVE LOW BLOOD PARATHYROID HORMONE LEVELS","EFO_0007937",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1323391694"
"93","PEGINTERFERON ALFA-2B","DB00022",NA,"IFNL3","ENSG00000197110","protein expression","positive",NA,"IFNL3 PROTEIN EXPRESSION POSITIVE","CHRONIC HEPATITIS","EFO_0008496",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG794218917"
"95","PRASUGREL","DB06209",NA,"CYP3A5","ENSG00000106258","protein expression","positive",NA,"CYP3A5 PROTEIN EXPRESSION POSITIVE","ATHEROSCLEROSIS","EFO_0003914",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1790679122"
"96","RUCAPARIB","DB12332",NA,"CYP1A2","ENSG00000140505","protein expression","positive",NA,"CYP1A2 PROTEIN EXPRESSION POSITIVE","OVARIAN CANCER","MONDO_0008170",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG149207443"
"98","USTEKINUMAB","DB05679",NA,"IL12A, IL12B, IL23A","ENSG00000168811, ENSG00000113302, ENSG00000110944","mutation,mutation,mutation","positive, positive, positive","AND/OR, AND/OR","IL12A MUTATION POSITIVE AND/OR IL12B MUTATION POSITIVE AND/OR IL23A MUTATION POSITIVE","COLITIS (UC)","EFO_0003872",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1053117702"
"99","VALPROIC ACID","DB00313",NA,"POLG","ENSG00000140521","mutation","positive",NA,"POLG MUTATION POSITIVE","EPILEPSY","EFO_0000474",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1944943287"
"100","VENETOCLAX","DB11581",NA,"TP53","ENSG00000141510","mutation","positive",NA,"TP53 MUTATION POSITIVE","LEUCOCYTHEMIA","EFO_0000222",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG1127858044"
"101","VENETOCLAX","DB11581",NA,"IGH","ENSG00000116017","translocation","positive",NA,"IGH TRANSLOCATION POSITIVE","LEUCOCYTHEMIA","EFO_0000222",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-1962047831"
"102","WARFARIN","DB00682",NA,"VKORC1","ENSG00000167397","polymorphism","positive",NA,"VKORC1 POLYMORPHISM POSITIVE","VENOUS THROMBOEMBOLIC DISEASE (VTE)","EFO_0004260",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-357946721"
"103","WARFARIN","DB00682",NA,"PROS1","ENSG00000184500","mutation","positive",NA,"PROS1 MUTATION POSITIVE","VENOUS THROMBOEMBOLIC DISEASE (VTE)","EFO_0004260",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG2028368899"
"104","WARFARIN","DB00682",NA,"PROC","ENSG00000115718","mutation","positive",NA,"PROC MUTATION POSITIVE","VENOUS THROMBOEMBOLIC DISEASE (VTE)","EFO_0004260",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG313586149"
"105","SODIUM   PHENYLBUTYRATE",NA,NA,"ASS1, CPS1, OTC","ENSG00000130707, ENSG00000021826, ENSG00000036473","mutation,mutation,mutation","positive, positive, positive","OR,OR","ASS1 MUTATION POSITIVE OR CPS1 MUTATION POSITIVE OR OTC MUTATION POSITIVE","ENZYME DEFICIENCY","Orphanet_309005",NA,"pass","Ben","FDA-drug_biomarkers-35-v2_BC_cleaned.xlsx","FDA","https://www.fda.gov/media/124784/download","BiomarkerKG-2104469395"
"109","NIVOLUMAB, IPILIMUMAB","DB09035,DB06186","NA, NA","ESR1, PGR, ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","Protein Expression, Protein expression, Protein Expression","Negative, Negative, Negative","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PD1, CTLA4","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03818685","BiomarkerKG1514699161"
"110","IMIPRAMINE","DB00458","8228","ESR1, PGR, ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","Protein Expression, Protein expression, Protein Expression & amplification","Negative, Negative, Negative","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","FoxM1","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03122444","BiomarkerKG-1435553749"
"112","PALBOCICLIB, LETROZOLE","DB09073,DB01006","11478676, 3902","ERBB2, PGR, ESR1","ENSG00000141736, ENSG00000082175, ENSG00000091831","Protein Expression, Protein expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","CDK4/CDK6, aromatase","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04047758","BiomarkerKG-1899271805"
"114","PYROTINIB, ETOPOSIDE","DB14993,DB00773","51039030, 36462","ERBB2","ENSG00000141736","Protein Expression & Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","ERBB2, Topoisomerase II/DNA","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03923179","BiomarkerKG809776760"
"115","DOCETAXEL, RITONAVIR","DB01248,DB00503","148124, 392622","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","RECURRENT BREAST CANCER","MONDO_0007254","Microtubles, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03890744","BiomarkerKG-1915782920"
"116","DURVALUMAB, TRASTUZUMAB, PERTUZUMAB","DB11714,DB00072,DB06366","NA, 3001322, NA","ERBB2, PGR, ESR1","ENSG00000141736, ENSG00000082175, ENSG00000091831","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER (I-II)","MONDO_0007254","PDL1, ERBB2, ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03820141","BiomarkerKG-156769428"
"117","PACLITAXEL, TRASTUZUMAB, CARBOPLATIN, PERTUZUMAB","DB01229,DB00072,DB00958,DB06366","36314, 3001322, 56840877, NA","ERBB2, PGR, ESR1","ENSG00000141736, ENSG00000082175, ENSG00000091831","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER (STAGE II-III)","MONDO_0007254","Bcl2, ERBB2, DNA/Protein, ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03820063","BiomarkerKG-1013990068"
"118","ONAPRISTONE","DB12637","5311505","ESR1, PGR, ERBB2, Ki67","ENSG00000091831, ENSG00000082175, ENSG00000141736, ENSG00000148773","Protein Expression, Protein expression, Protein Expression, Protein expression","Positive, Positive, Negative, Positive","AND, AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (I-II)","MONDO_0007254","progesterone receptor","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04142892","BiomarkerKG-447481596"
"119","PEMBROLIZUMAB, PEGYLATED LIPOSOMAL DOXORUBICIN","DB09037,NA","NA, NA","ESR1, ERBB2","ENSG00000091831, ENSG00000141736","Protein Expression, Protein Expression","Positive, Negative","AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER (III-IV)","MONDO_0007254","PD1, Topoisomerase II/DNA","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03591276","BiomarkerKG-859329038"
"120","PYROTINIB, CAPECITABINE","DB14993,DB01101","51039030, 60953","ERBB2","ENSG00000141736","Protein Expression & Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","BREAST CANCER","MONDO_0007254","ERBB2, DNA/RNA/Protein Synthesis","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03923166","BiomarkerKG687053448"
"121","PEMBROLIZUMAB, PACLITAXEL","DB09037,DB01229","NA, 36314","ESR1, ERBB2, Ki67","ENSG00000091831, ENSG00000141736, ENSG00000148773","Protein Expression, Protein expression, Protein Expression","Positive, Negative, Positive","AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC LUMINAL B BREAST CANCER","MONDO_0007254","PDL, Bcl2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03841747","BiomarkerKG-889764113"
"122","PYROTINIB, ALBUMIN-BOUND PACLITAXEL, TRASTUZUMAB, EPRIRUBICIN, CYCLOPHOSPHAMIDE","DB14993,NA,DB00072,NA,DB00531","51039030, NA, 3001322, NA, 2907","ERBB2","ENSG00000141736","Protein Expression &Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION &AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","BREAST CANCER (I-III)","MONDO_0007254","ERBB2, GP60/Bcl2, ERBB2, Topoisomerase II/DNA, DNA","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04066790","BiomarkerKG-103720969"
"125","PYROTINIB","DB14993","51039030","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03980054","BiomarkerKG-1504794440"
"127","LETROZOLE, PYROTINIB, SHR6390","DB01006,DB14993,NA","3902, 51039030, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","Aromatase, ERBB2, CDK4/CDK6","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03772353","BiomarkerKG1827935371"
"128","CAPECITABINE","DB01101","60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein expression, Protein Expression","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","NON-METASTATIC INVASIVE BREAST CANCER","MONDO_0007254","DNA/RNA/Protein Synthesis","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03958721","BiomarkerKG1686449390"
"129","DOCETAXEL, CYCLOPHOSPHAMIDE, TRASTUZUMAB","DB01248,DB00531,DB00072","148124, 2907, 3001322","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","BREAST NEOPLASMS","MONDO_0007254","microtubles/VEGF, DNA, ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03705429","BiomarkerKG-435072881"
"131","SAR439859",NA,"130232326","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","ESR1","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03816839","BiomarkerKG1596444665"
"133","IPATASERTIB, PALBOCICLIB, FULVESTRANT","DB11743,DB09073,DB00947","24788740, 11478676, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC BREAST CANCER","MONDO_0007254","Akt, CDK4/CDK6, ER","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04060862","BiomarkerKG-316459000"
"134","ERIBULIN, BALIXAFORTIDE","DB08871,DB15370","17755248, 138752609","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","LOCALLY RECURRENT OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03786094","BiomarkerKG1503939067"
"136","VENETOCLAX, PALBOCICLIB, LETROZOLE","DB11581,DB09073,DB01006","49846579, 11478676, 3902","ESR1, Bcl2, ERBB2","ENSG00000091831, ENSG00000171791, ENSG00000141736","Protein Expression, Protein expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND BCL2 PROTEIN EXPRESSION POSITIVE AND/OR ERBB2 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, CDK4/CDK6, aromatase","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03900884","BiomarkerKG-2032842044"
"138","ATEZOLIZUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB EMTANSINE","DB11595,DB00997,DB00531,DB01229,DB06366,DB05773","NA, 443939, 2907, 36314, NA, NA","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein expression, Protein Expression, Protein expression","Positive, Positive/Negative, Positive/Negative, Positive/Negative","AND, AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","BREAST CANCER (I-III)","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03726879","BiomarkerKG276424285"
"139","FS-1502",NA,"2760428","ERBB2","ENSG00000141736","Protein Expression & Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","ERBB2","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03944499","BiomarkerKG1623818552"
"140","IPI-549, ATEZOLIZUMAB, NAB-PACLITAXEL","NA,DB11595,NA","91933883, NA, 36314","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","PI3Kgamma, PDL1, microtubles","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03961698","BiomarkerKG-627703212"
"141","ALL-TRANS RETINOIC ACID, ANASTROZOLE","NA,DB01217","444795, 2187","ESR1, ERBB2, Ki67","ENSG00000091831, ENSG00000141736, ENSG00000148773","Protein Expression, Protein expression, Protein Expression","Positive, Negative, Positive","AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST NEOPLASM","EFO_0003869","RARα, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04113863","BiomarkerKG-1795461556"
"142","PYROTINIB, CAPECITABINE","DB14993,DB01101","51039030, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression & Amplification, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","EGFR/ERBB2/HER4, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04001621","BiomarkerKG1649159632"
"144","NIVOLUMAB, IPILIMUMAB, BICALUTAMIDE","DB09035,DB06186,DB01128","NA, NA, 2375","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BREAST CANCER","MONDO_0007254","PD1, CTLA4, AR","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03650894","BiomarkerKG-1239420556"
"145","NAB-PACLITAXEL, CARBOPLATIN, CAPECITABINE","NA,DB00958,DB01101","36314, 56840877, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","ADVANCED TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04159142","BiomarkerKG-2135616330"
"146","RIBOCICLIB, TRASTUZUMAB, LETROZOLE","DB11730,DB00072,DB01006","44631912, 3001322, 3902","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression and Amplification, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION AND AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","POSTMENOPAUSAL ADVANCED METASTATIC BREAST CANCER","MONDO_0007254","CDK4/CDK6, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03913234","BiomarkerKG2061889424"
"147","LETROZOLE, PALBOCICLIB","DB01006,DB09073","3902, 11478676","ERBB2, ESR1, PGR, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER (II-IIIB)","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03819010","BiomarkerKG905609745"
"148","PYROTINIB, TRASTUZUMAB, DOCETAXEL, CARBOPLATIN","DB14993,DB00072,DB01248,DB00958","51039030, 3001322, 148124, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03756064","BiomarkerKG345427327"
"149","COPANLISIB, TRASTUZUMAB EMTANSINE","DB12483,DB05773","135565596, NA","ERBB2","ENSG00000141736","Protein Expression & Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","UNRESECTABLE LOCALLY ADVANCED OR METASTATIC  BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04042051","BiomarkerKG702885081"
"150","ATEZOLIZUMAB, CAPECITABINE","DB11595,DB01101","NA, 60953","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PDL1, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03756298","BiomarkerKG-1430355371"
"154","DURVALUMAB, OLAPARIB, FULVESTRANT","DB11714,DB09074,DB00947","NA, 23725625, 104741","ERBB2, ESR1, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FAND2, FANCL, MRE11A, NBN, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L, AKT1, FGFR1, FGFR2, FGFR3, PIK3CA","ENSG00000141736, ENSG00000091831, ENSG00000149311, ENSG00000138376, ENSG00000012048, ENSG00000139618, ENSG00000136492, ENSG00000167258, ENSG00000149554, ENSG00000183765, ENSG00000187741, NA, ENSG00000115392, ENSG00000020922, ENSG00000104320, ENSG00000083093, ENSG00000221914, ENSG00000182185, ENSG00000108384, ENSG00000185379, ENSG00000085224, ENSG00000142208, ENSG00000077782, ENSG00000066468, ENSG00000068078, ENSG00000121879","Protein Expression, Protein Expression/mutation, mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation,  mutation, mutation, mutation, mutation","Negative, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive, Positive","AND, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION/MUTATION POSITIVE AND/OR ATM MUTATION POSITIVE AND/OR BARD1 MUTATION POSITIVE AND/OR BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND/OR BRIP1 MUTATION POSITIVE AND/OR CDK12 MUTATION POSITIVE AND/OR CHEK1 MUTATION POSITIVE AND/OR CHEK2 MUTATION POSITIVE AND/OR FANCA MUTATION POSITIVE AND/OR FAND2 MUTATION POSITIVE AND/OR FANCL MUTATION POSITIVE AND/OR MRE11A MUTATION POSITIVE AND/OR NBN MUTATION POSITIVE AND/OR PALB2 MUTATION POSITIVE AND/OR PPP2R2A MUTATION POSITIVE AND/OR RAD51B MUTATION POSITIVE AND/OR RAD51C MUTATION POSITIVE AND/OR RAD51D MUTATION POSITIVE AND/OR RAD54L MUTATION POSITIVE AND/OR AKT1 MUTATION POSITIVE AND/OR FGFR1 MUTATION POSITIVE AND/OR FGFR2 MUTATION POSITIVE AND/OR FGFR3 MUTATION POSITIVE AND/OR PIK3CA MUTATION POSITIVE","METASTATIC OR LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04053322","BiomarkerKG-1139236655"
"155","PYROTINIB MALEATE, DOCETAXEL","NA,DB01248","138115215, 148124","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03876587","BiomarkerKG1505390240"
"156","TESETAXEL, CAPECITABINE","DB12019,DB01101","6918574, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03858972","BiomarkerKG-2093307115"
"157","PYROTINIB MALEATE, ALBUMIN PACLITAXEL, TRASTUZUMAB","NA,NA,DB00072","138115215, NA, 3001322","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","EARLY OR LOCALLY ADVANCED BREAST CANCER (II-III)","MONDO_0007254","EGFR/ERBB2, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04152057","BiomarkerKG729598124"
"158","OLAPARIB","DB09074","23725625","ERBB2, ESR1, PGR, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression, Protein Expression, Protein Expression, mutation, mutation","Positive/Negative, Positive/Negative, Positive/Negative, Negative, Negative","AND/OR, AND/OR, AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","METASTATIC MALIGNANT NEOPLASM IN THE CHEST WALL","EFO_1000051","PARP","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03955640","BiomarkerKG-1616092040"
"159","PALBOCICLIB, LETROZOLE","DB09073,DB01006","11478676, 3902","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER STAGE IV","MONDO_0007254","CDK4/CDK6, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03870919","BiomarkerKG-226063560"
"160","PYROTINIB, TRASTUZUMAB, DOCETAXEL","DB14993,DB00072,DB01248","51039030, 3001322, 148124","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03863223","BiomarkerKG-601099740"
"161","SACITUZUMAB GOVITECAN","DB12893","91668186","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC OR LOCALLY RECURRENT INOPERABLE BREAST CANCER","MONDO_0007254","Trop2/SN38/CL2A","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03901339","BiomarkerKG-274333150"
"162","NERATINIB, PACLITAXEL, CARBOPLATIN","DB11828,DB01229,DB00958","9915743, 36314, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","EARLY STAGE TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03812393","BiomarkerKG921194961"
"163","PALBOCICLIB, BOSUTINIB, FULVESTRANT","DB09073,DB06616,DB00947","11478676, 5328940, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCOREGIONALLY RECURRENT OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03854903","BiomarkerKG-1540813963"
"165","LERONLIMAB, CARBOPLATIN","DB05941,DB00958","NA, 56840877","ERBB2, CCR5, ESR1, PGR","ENSG00000141736, ENSG00000160791, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Negative, Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND CCR5 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254","CCR5, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03838367","BiomarkerKG1068866669"
"166","LY3023414, PREXASERTIB","NA,DB12008","57519748, 46700756","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","non-homologous end joining, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04032080","BiomarkerKG-1471164927"
"167","NAB-PACLITAXEL, CARBOPLATIN, EPIRUBICIN, CYCLOPHOSPHAMIDE","NA,DB00958,DB00445,DB00531","36314, 56840877, 65348, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04067102","BiomarkerKG-57313394"
"169","ABEMACICLIB, COPANLISIB, COPANLISIB HYDROCHLORIDE, FULVESTRANT","DB12001,DB12483,NA,DB00947","46220502, 135565596, 135565785, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, PI3K, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03939897","BiomarkerKG-617297347"
"170","PYROTINIB MALEATE, ALBUMIN PACLITAXEL, TRASTUZUMAB, EPIRUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE","NA,NA,DB00072,NA,DB00531","138115215, NA, 3001322, 65348, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","EARLY OR LOCALLY ADVANCED BREAST CANCER (II-III)","MONDO_0007254","EGFR/ERBB2, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04152057","BiomarkerKG-891847787"
"172","PEMBROLIZUMAB, LENVATINIB","DB09037,DB09078","NA, 11237762","ERBB2, ESR1, PGR, LDH","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000134333","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND LDH PROTEIN EXPRESSION POSITIVE","ADVANCED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03797326","BiomarkerKG1568508684"
"180","9-ING-41, GEMCITABINE, DOXORUBICIN, LOMUSTINE, CARBOPLATIN, NAB PACLITAXEL, PACLITAXEL, IRINOTECAN","NA,DB00441,DB00997,DB01206,DB00958,NA,DB01229,DB00762","44582816, 60750, 443939, 3950, 56840877, 36314, 36314, 60838","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive/Negative, Positive/Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","GSK-3β, UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03678883","BiomarkerKG551843489"
"184","NAPTUMOMAB ESTAFENATOX, DURVALUMAB","DB12807,DB11714","NA, NA","ERBB2, ESR1, PGR, 5T4","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000146242","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive/Negative","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND 5T4 PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03983954","BiomarkerKG1477271139"
"185","NAPTUMOMAB ESTAFENATOX, DURVALUMAB","DB12807,DB11714","NA, NA","ERBB2, ESR1, 5T4","ENSG00000141736, ENSG00000091831, ENSG00000146242","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Positive/Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND 5T4 PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03983954","BiomarkerKG285317920"
"187","REBASTINIB, CARBOPLATIN","DB13005,DB00958","25066467, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03717415","BiomarkerKG-482905584"
"195","PYROTINIB, SHR6390, LETROZOLE","DB14993,NA,DB01006","51039030, NA, 3902","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein Expression & Amplification, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04095390","BiomarkerKG-1661914186"
"196","PYROTINIB, SHR6390, CAPECITABINE","DB14993,NA,DB01101","51039030, NA, 60953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression/Protein expression & Amplification, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04095390","BiomarkerKG-1814161762"
"199","ATEZOLIZUMAB, IPATASERTIB, PACLITAXEL","DB11595,DB11743,DB01229","NA, 24788740, 36314","ERBB2, ESR1, PGR, PDL1, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217, ENSG00000012048, ENSG00000139618","Protein Expression, Protein Expression, Protein Expression, Protein Expression, Mutation, Mutation","Negative, Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04177108","BiomarkerKG-437004938"
"201","NIVOLUMAB, ABEMACICLIB, ANASTROZOLE, PALBOCICLIB","DB09035,DB12001,DB01217,DB09073","NA, 46220502, 2187, 11478676","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04075604","BiomarkerKG-1110084195"
"202","NIVOLUMAB, DOXORUBICIN","DB09035,DB00997","NA, 443939","ERBB2, ESR1, PGR, Ki67","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000148773","Protein Expression, Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","RESECTABLE PRIMARY TRIPLE NEGATIVE BREAST CANCER (STAGE I-III)","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03815890","BiomarkerKG1364396589"
"204","NIVOLUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","DB09035,DB01229,DB00997,DB00531","NA, 36314, 443939, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INFLAMMATORY TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03742986","BiomarkerKG-1448510916"
"205","NIVOLUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, TRASTUZUMAB, PERTUZUMAB","DB09035,DB01229,DB00997,DB00531,DB00072,DB06366","NA, 36314, 443939, 2907, 3001322, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Positive, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE","INFLAMMATORY BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03742986","BiomarkerKG-2022083316"
"207","ABEMACICLIB, DURVALUMAB, AROMATASE INHIBITOR","DB12001,DB11714,NA","46220502, NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED BREAST CANCER (II-III)","MONDO_0007254","UNK, UNK, aromatase","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04088032","BiomarkerKG356324322"
"208","PACLITAXEL, CARBOPLATIN, CYCLOPHOSPHAMIDE","DB01229,DB00958,DB00531","36314, 56840877, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE INVASIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03858322","BiomarkerKG-104675348"
"210","RIBOCICLIB, ENDOCRINE THERAPY","DB11730,NA","44631912, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","VISCERAL METASTATIC BREAST CANCER","MONDO_0007254","UNK, UNK","pass","ALV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03905343","BiomarkerKG-1384231495"
"211","ENTINOSTAT, CAPECITABINE","DB11841,DB01101","4261, 60953","ESR1, PGR, ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","protein expression, protein expression, protein expression","Positve/negative, positive/negative, negative","OR, AND","ESR1 PROTEIN EXPRESSION POSITVE/NEGATIVE OR PGR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER, BREAST CANCER","MONDO_0007254","HDAC, DNA/RNA/Protein Synthesis","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03473639","BiomarkerKG34334946"
"212","TALAZOPARIB, SACITUZUMAB GOVITECAN","DB11760,DB12893","135565082, 91668186","ESR1, PGR, ERBB2","ENSG00000091831, ENSG00000082175, ENSG00000141736","protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254","PARP, Topoisomerase I-DNA covalent complexes","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04039230","BiomarkerKG1946912801"
"213","TRASTUZUMAB, GDC-0084","DB00072,DB15186","3001322, 57384863","ERBB2","ENSG00000141736","protein expression & amplification","Positve",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITVE","ERBB2-POSITIVE BREAST CANCER BRAIN METASTASES","MONDO_0007254","ERBB2, PI3-Kinase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03765983","BiomarkerKG-1577117464"
"214","ASPIRIN, TAMOXIFEN, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL","DB00945,DB00675,DB00997,DB00531,DB01229","2244, 2733526, 443939, 2907, 36314","ESR1, ERBB2","ENSG00000091831, ENSG00000141736","protein expression, protein expression","Positve, negative","AND","ESR1 PROTEIN EXPRESSION POSITVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER (STAGE I-III)","MONDO_0007254","COX, Estrogen Receptors, DNA/DNA-topoisomerase II complex, DNA, Bcl2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04038489","BiomarkerKG-2085566364"
"215","NAB-PACLITAXEL",NA,"36314","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Positive/Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","PRIMARY INVASIVE BREAST CANCER AND CLINICAL STAGE I - III, FIRST OPTION Ⅳ","MONDO_0007254","Bcl2/GP60","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03959397","BiomarkerKG-1363681835"
"216","NIVOLUMAB, IPILIMUMAB","DB09035,DB06186","NA, NA","ERBB2, ER, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, negative/positive, negative/positive","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND/OR ER PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","PD1, CTLA4","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03789110","BiomarkerKG-1494023734"
"217","SIMVASTATIN","DB00641","54454","ERBB2","ENSG00000141736","protein expression & amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","BREAST CANCER STAGE (STAGE IV)","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03324425","BiomarkerKG1251372237"
"218","PEMBROLIZUMAB, TAMOXIFEN","DB09037,DB00675","NA, 2733526","ESR1, ERBB2, PGR","ENSG00000091831, ENSG00000141736, ENSG00000082175","mutation, protein expression, protein expression","Positve, negative, positive","AND, AND/OR","ESR1 MUTATION POSITVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","BREAST CANCER FEMALE","MONDO_0007254","PD1, Estrogen Receptors","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03879174","BiomarkerKG-153611909"
"219","APATINIB, PACLITAXEL, CISPLATIN","DB14765,DB01229,DB00515","45139106, 36314, 2767","ERBB2","ENSG00000141736","protein expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER","MONDO_0007254","VEGFR2, Bcl2, Replication and transcription of DNA","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03982485","BiomarkerKG351003137"
"220","PALBOCICLIB","DB09073","11478676","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression, protein expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER STAGE (STAGE II-III)","MONDO_0007254","CDK4/CDK6","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03609047","BiomarkerKG-1579678160"
"222","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB, EPIRUBICIN, CYCLOPHOSPHAMIDE, ATEZOLIZUMAB, TRASTUZUMAB EMTANSINE","DB01248,DB00958,DB00072,DB06366,DB00445,DB00531,DB11595,DB05773","148124, 56840877, 3001322, NA, 65348, 2907, NA, NA","ERBB2, ESR1, PGR, PDl1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","protein expression & amplification, protein expression, protein expression, protein expression","Positive, positive, positive, positve","AND, AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE AND PDL1 PROTEIN EXPRESSION POSITVE","EARLY-STAGE BREAST CANCER","MONDO_0007254","VEGF/microtubule, DNA/Protein, ERBB2, ERBB2,  DNA/DNA-topoisomerase II complex, DNA, CD274, microtubules","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03894007","BiomarkerKG118603023"
"223","OLAPARIB, VORINOSTAT","DB09074,DB02546","23725625, 5311","ERBB2","ENSG00000141736","protein expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","BREAST CANCER METASTATIC, BREAST CANCER","MONDO_0007254","PARP, HDAC","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03742245","BiomarkerKG1189074014"
"225","NIRAPARIB, TRASTUZUMAB","DB11793,DB00072","24958200, 3001322","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression & amplification, protein expression, protein expression","Positive, negativie/positive, negative/positive","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION NEGATIVIE/POSITIVE AND/OR PR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER, ERBB2 POSITIVE BREAST CARCINOMA","MONDO_0007254","PARP1/PARP2, ERBB2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03368729","BiomarkerKG-388096993"
"226","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB","DB01248,DB00958,DB00072,DB06366","148124, 56840877, 3001322, NA","ERBB2","ENSG00000141736","protein expression & amplification","Positve",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITVE","INVASIVE BREAST CARCINOMA","EFO_1000307","VEGF/microtuble, DNA/Protein, ERBB2, ERBB2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04094896","BiomarkerKG1874182044"
"229","NIVOLUMAB, PACLITAXEL, ANTHRACYCLINE, CYCLOPHOSPHAMIDE, ENDOCRINE THERAPY","DB09035,DB01229,NA,DB00531,NA","NA, 36314, NA, 2907, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, positive, negative/positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","BREAST CANCER","MONDO_0007254","PD1, Bcl2, DNA/DNA-topoisomerase II complex, DNA,  hormone receptors","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04109066","BiomarkerKG2087957969"
"231","RUCAPARIB","DB12332","9931953","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TNBC BREAST CANCER  (STAGE I-III)","MONDO_0007254","PDL1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03911453","BiomarkerKG1644765431"
"233","PALBOCICLIB, LETROZOLE, TRASTUZUMAB, PERTUZUMAB","DB09073,DB01006,DB00072,DB06366","11478676, 3902, 3001322, NA","ESR1, ERBB2","ENSG00000091831, ENSG00000141736","protein expression, protein expression/protein expression & amplification","Positive, Positive","AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION/PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","BREAST CANCER","MONDO_0007254","CDK4/CDK6, aromatase, ERBB2, ERBB2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03644186","BiomarkerKG-262451806"
"235","ERIBULIN","DB08871","17755248","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, negative/positive, negative/positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","Tubulin","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03637868","BiomarkerKG-1083648118"
"236","RIBOCICLIB, LETROZOLE OR ANASTROZOLE, GOSERELIN","DB11730,NA,DB00014","44631912, NA, 5311128","ERBB2, PGR,ESR1","ENSG00000141736, ENSG00000082175, ENSG00000091831","protein expression, protein expression, protein expression","Negative, positive, positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","CDK4/CDK6, aromatase OR aromatase, GnRH receptors","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03822468","BiomarkerKG-225817822"
"237","IPILIMUMAB, NIVOLUMAB","DB06186,DB09035","NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TNBC BREAST CANCER","MONDO_0007254","CTLA4, PD1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03546686","BiomarkerKG-2009160467"
"239","PALBOCICLIB, EXEMESTANE, GOSERELIN","DB09073,DB00990,DB00014","11478676, 60198, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, positive, positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","CDK4/CDK6, aromatase, GnRH receptors","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT02917005","BiomarkerKG-1723002468"
"241","RIBOCICLIB, LETROZOLE","DB11730,DB01006","44631912, 3902","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, Positive, negative/positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","NON-METASTATIC PRIMARY LUMINAL BREAST CANCER (STAGE II-III)","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03283384","BiomarkerKG-604627963"
"242","ERIBULIN, NIVOLUMAB","DB08871,DB09035","17755248, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression, protein expression","Negative, negative/positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04061863","BiomarkerKG-1030601521"
"243","PEMBROLIZUMAB, TRASTUZUMAB BIOSIMILAR ABP 980, PERTUZUMAB","DB09037,NA,DB06366","NA, NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression & amplification, protein expression, protein expression","Positive, negative/positive, negative/positive","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03988036","BiomarkerKG138689674"
"244","CFI-400945, DURVALUMAB","NA,DB11714","58486178, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TNBC BREAST CANCER","MONDO_0007254","PLK4, PDl1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04176848","BiomarkerKG397892956"
"245","RIBOCICLIB, LETROZOLE OR ANASTROZOLE, GOSERELIN","DB11730,NA,DB00014","44631912, NA, 5311128","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression, protein expression, protein expression","Negative, positive, positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","PREMENOPAUSAL OR PERIMENOPAUSAL LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03839823","BiomarkerKG721208190"
"247","CHIDAMIDE, CISPLATIN","DB06334,DB00515","9800555, 2767","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04192903","BiomarkerKG1288315268"
"248","PYROTINIB, FULVESTRANT","DB14993,DB00947","51039030, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression&amplification, protein expression, protein expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","TK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04034589","BiomarkerKG-2056951534"
"249","LASOFOXIFENE","DB06202","216416","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression, protein expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC BREAST CANCER","MONDO_0007254","ER Receptor","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03781063","BiomarkerKG-1897970195"
"251","OLAPARIB, TRASTUZUMAB","DB09074,DB00072","23725625, 3001322","BRCA1,BRCA2, ERBB2","ENSG00000012048, ENSG00000139618, ENSG00000141736","mutation, mutation, protein expression&amplification","Positive, Positive, Positive","AND/OR, AND","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","RECURRENT OR METASTATIC BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03931551","BiomarkerKG996483862"
"255","ABEMACICLIB, FULVESTRANT","DB12001,DB00947","46220502, 104741","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04031885","BiomarkerKG-1884678499"
"257","PEMBROLIZUMAB","DB09037",NA,"ESR1, PGR","ENSG00000091831, ENSG00000082175","protein expression, protein expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","STAGE IV METASTATIC BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03492918","BiomarkerKG1863117410"
"259","PYROTINIB, VINORELBINE","DB14993,DB00361","51039030, 5311497","ERBB2","ENSG00000141736","Protein expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03997539","BiomarkerKG289580844"
"260","PALBOCICLIB, ENDOCRINE THERAPY","DB09073,NA","11478676, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","RECURRENT BREAST CANCER","MONDO_0007254","CDK4/CDK6, Hormone receptors","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03820830","BiomarkerKG-2074888963"
"261","DURVALUMAB, ENDOCRINE THERAPY","DB11714,NA","NA, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein expression, protein expression","negative, positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, aromatase inhibitor","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03874325","BiomarkerKG1360761977"
"262","LYNPARZA",NA,"23725625","BRCA1,BRCA2, ERBB2, ESR1, PGR","ENSG00000012048, ENSG00000139618, ENSG00000141736, ENSG00000091831, ENSG00000082175","Mutation, mutation, protein expression, protein expression, protein expression","Positive, positive, negative, negative, negative","AND/OR, AND, AND, AND","BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04041128","BiomarkerKG1586324685"
"265","VINORELBINE, APATINIB","DB00361,DB14765","5311497, 45139106","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, VEGF2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03932526","BiomarkerKG-1645794555"
"266","ABEMACICLIB, ANASTROZOLE, FULVESTRANT, LETROZOLE, PALBOCICLIB, RIBOCICLIB","DB12001,DB01217,DB00947,DB01006,DB09073,DB11730","46220502, 2187, 104741, 3902, 11478676, 44631912","ESR1, PGR","ENSG00000091831, ENSG00000082175","Protein expression, protein expression","Positive, Positive","AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","CDK4/CDK6, UNK, UNK, UNK, CDK4/CDK6, CDK4/CDK6","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04256941","BiomarkerKG-1304175737"
"267","PACLITAXEL, NAB-PACLITAXEL, ATEZOLIZUMAB","DB01229,NA,DB11595","36314, 36314, NA","ERBB2, ESR1, PGR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000120217","Protein expression, protein expression, protein expression, protein expression","Negative, negative, negative, positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04148911","BiomarkerKG-1019298398"
"269","CARBOPLATIN, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE","DB00958,DB01229,DB00997,DB00531","56840877, 36314, 443939, 2907","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04083963","BiomarkerKG67951044"
"270","NIRAPARIB","DB11793","24958200","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03945721","BiomarkerKG1857107666"
"273","CAMRELIZUMAB, NAB-PACLITAXEL, FAMITINIB","DB14776,NA,DB11741","NA, 36314, 16662431","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04129996","BiomarkerKG735236579"
"275","NAB-PACLITAXEL, EPIRUBICIN, CARBOPLATIN","NA,DB00445,DB00958","36314, 65348, 56840877","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04138719","BiomarkerKG-800369839"
"277","CRIZOTINIB, FULVESTRANT","DB08865,DB00947","11626560, 104741","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression, protein expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, oestrogen receptor","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03620643","BiomarkerKG-835107575"
"278","PYROTINIB MALEATE, NAB-PACLITAXEL","NA,NA","138115215, 36314","ERBB2","ENSG00000141736","protein expression&amplification/protein expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03919253","BiomarkerKG-293355652"
"279","PEMBROLIZUMAB","DB09037",NA,"ERBB2, APOBEC3B, ER","ENSG00000141736, ENSG00000179750, ENSG00000091831","protein expression, mutation, protein expression","Negative, Positive, negative/positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND APOBEC3B MUTATION POSITIVE AND ER PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03989089","BiomarkerKG-1189924932"
"280","PEMBROLIZUMAB, CARBOPLATIN, GEMCITABINE, OLAPARIB","DB09037,DB00958,DB00441,DB09074","NA, 56840877, 60750, 23725625","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04191135","BiomarkerKG-1632658776"
"282","PYROTINIB, TRASTUZUMAB, VINORELBINE","DB14993,DB00072,DB00361","51039030, 3001322, 5311497","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","protein expression&amplification/protein expression, protein expression, protein expression","Positive, negative/positive, negative/positive","AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","HER1/HER2, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03947242","BiomarkerKG358990573"
"283","PYROTINIB, TRASTUZUMAB, DOCETAXEL, CARBOPLATIN","DB14993,DB00072,DB01248,DB00958","51039030, 3001322, 148124, 56840877","ERBB2","ENSG00000141736","protein expression&amplification/protein expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","EARLY STAGE OR LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03847818","BiomarkerKG-1876496357"
"284","DOCETAXEL, ATEZOLIZUMAB, TRASTUZUMAB SC, PERTUZUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE, HERCEPTIN SC","DB01248,DB11595,NA,DB06366,DB00997,DB00531,NA","148124, NA, NA, NA, 443939, 2907, NA","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression&amplification/protein expression, protein expression","Positive, negative/positive","AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","LOCALLY ADVANCED","EFO_0005856","UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03881878","BiomarkerKG-33556113"
"285","TUCATINIB, T-DM1","DB11652,DB05773","51039094, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Positive, negative/positive, negative/positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03975647","BiomarkerKG-599028211"
"286","SPARTALIZUMAB, LAG525, NIR178, CAPMATINIB, MCS110, CANAKINUMAB","DB14892,NA,NA,DB11791,NA,DB06168","NA, NA, NA, 25145656, NA, NA","ERBB2, ESR1, PGR","ENSG00000141736, ENSG00000091831, ENSG00000082175","Protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03742349","BiomarkerKG1688452319"
"291","CARBOPLATIN, PACLITAXEL","DB00958,DB01229","56840877, 36314","ERBB2, ESR1, PGR, BRCA1, BRCA2","ENSG00000141736, ENSG00000091831, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression, Protein expression, Protein expression, Mutation, Mutation","Negative, Negative, Negative, Positive, Positive","AND, AND, AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03876886","BiomarkerKG-453264115"
"292","BERZOSERTIB","DB11794","59472121","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","ATR Kinase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04052555","BiomarkerKG-1503610555"
"295","OLECLUMAB, DURVALUMAB","DB15088,DB11714","NA, NA","ERBB2, ERS1, Ki67, PDL1","ENSG00000141736, NA, ENSG00000148773, ENSG00000120217","Protein Expression, Protein expression, Protein expression, Protein Expression","Negative, Positive, Negative/Positive, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","LUMINAL B BREAST CANCER","MONDO_0007254","CD73, PDL1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov"," NCT03875573","BiomarkerKG179888471"
"296","CARBOPLATIN, IPATASERTIB, PACLITAXEL","DB00958,DB11743,DB01229","56840877, 24788740, 36314","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03853707","BiomarkerKG1995732573"
"297","PALBOCICLIB, ENDOCRINE THERAPY","DB09073,NA","11478676, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov"," NCT03809988","BiomarkerKG1739611934"
"298","CAPIVASERTIB, PACLITAXEL","DB12218,DB01229","25227436, 36314","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03997123","BiomarkerKG-915701665"
"300","ALPELISIB, ENZALUTAMIDE","DB12015,DB08899","56649450, 15951529","ERBB2, ERS1, PGR, AR, PTEN","ENSG00000141736, NA, ENSG00000082175, ENSG00000169083, ENSG00000171862","Protein Expression, Protein expression, Protein expression, Protein Expression, Mutation","Negative,Positive,Positive, Positive, Positive","AND, AND/OR, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND AR PROTEIN EXPRESSION POSITIVE AND PTEN MUTATION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","Phosphoinositide 3-kinase, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03207529","BiomarkerKG-689338926"
"302","IPATASERTIB, RUCAPARIB","DB11743,DB12332","24788740, 9931953","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03840200","BiomarkerKG-975392028"
"304","PERTUZUMAB, TRASTUZUMAB, COPANLISIB","DB06366,DB00072,DB12483","NA, 3001322, 135565596","ERBB2, ERS1, PGR, PTEN, PIK3CA","ENSG00000141736, NA, ENSG00000082175, ENSG00000171862, ENSG00000121879","Protein expression&amplification, Protein Expression, Protein expression, Mutation, Mutation","Positive, Negative/Positive, Negative/Positive, Positive, Positive","AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PTEN MUTATION POSITIVE AND PIK3CA MUTATION POSITIVE","ADVANCED BREAST CANCER","MONDO_0007254","UNK, ERBB2, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04108858","BiomarkerKG2065001521"
"305","PACLITAXEL, TALIMOGENE LAHERPAREPVEC","DB01229,DB13896","36314, NA","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC OR LOCOREGIONALLY RECCURENT BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03554044","BiomarkerKG-170542798"
"306","TAMOXIFEN, TALIMOGENE LAHERPAREPVEC, LETROZOLE, FULVESTRANT, EXEMESTANE, ANASTROZOLE","DB00675,DB13896,DB01006,DB00947,DB00990,DB01217","2733526, NA, 3902, 104741, 60198, 2187","ERBB2, ERS1","ENSG00000141736, NA","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","METASTATIC OR LOCOREGIONALLY RECCURENT BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03554044","BiomarkerKG-743019303"
"307","COPANLISIB, FULVESTRANT","DB12483,DB00947","135565596, 104741","ERBB2, ERS1, PIK3CA, PTEN","ENSG00000141736, NA, ENSG00000121879, ENSG00000171862","Protein Expression, Protein Expression, Mutation, Mutation","Negative, Positive, Negative/Positive, Negative/Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND PIK3CA MUTATION NEGATIVE/POSITIVE AND PTEN MUTATION NEGATIVE/POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","PI3K, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03803761","BiomarkerKG302277995"
"308","AVELUMAB, BINIMETINIB, PF-04518600, UTOMILUMAB","DB11945,DB11967,NA,DB15113","NA, 10288191, NA, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","STAGE IV TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, OX40, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03971409","BiomarkerKG-635888986"
"309","PYROTINIB, TRASTUZUMAB, AROMATASE INHIBITORS","DB14993,DB00072,NA","51039030, 3001322, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","ADVANCED INVASIVE BREAST CANCER","MONDO_0007254","UNK, UNK, Aromatase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04088110","BiomarkerKG-544075815"
"311","LEFLUNOMIDE","DB01097","3899","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","dihydroorotate dehydrogenase","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03709446","BiomarkerKG-820225238"
"312","TESETAXEL, NIVOLUMAB, PEMBROLIZUMAB, ATEZOLIZUMAB","DB12019,DB09035,DB09037,DB11595","6918574, NA, NA, NA","ERBB2, ERS1, PGR, PDL1","ENSG00000141736, NA, ENSG00000082175, ENSG00000120217","Protein Expression, Protein expression, Protein expression, protein expression","Negative, Negative, Negative, Negative/positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND PDL1 PROTEIN EXPRESSION NEGATIVE/POSITIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03952325","BiomarkerKG-10442632"
"313","TESETAXEL","DB12019","6918574","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03952325","BiomarkerKG-1944338472"
"314","TAMOXIFEN","DB00675","2733526","BRCA1, BRCA2, ESR1","ENSG00000012048, ENSG00000139618, ENSG00000091831","Mutation, Mutation, Protein Expression","Negative, Negative, Positive","AND, AND","BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","BREAST DUCTAL CARCINOMA IN SITU","EFO_0000432","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04046159","BiomarkerKG-1575067713"
"315","CELECOXIB, CYCLOPHOSPHAMIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, RECOMBINANT INTERFERON ALFA-2B, RINTATOLIMOD","DB00482,DB00531,DB00997,NA,DB01229,NA,NA","2662, 2907, 443939, 443939, 36314, NA, 135537060","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","EARLY STAGE TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04081389","BiomarkerKG-1945881394"
"316","ATEZOLIZUMAB, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB","DB11595,DB01229,DB06366,DB00072","NA, 36314, NA, 3001322","ERBB2, ERS1, PGR, PDL1","ENSG00000141736, NA, ENSG00000082175, ENSG00000120217","Protein expression&amplification, Protein Expression, Protein expression, protein expression","Positive, Negative/Positive, Negative/Positive, Positive","AND, AND, AND","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE AND PDL1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK, ERBB2","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03199885","BiomarkerKG-1955995515"
"317","CYCLOPHOSPHAMIDE, LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBICIN","DB00531,NA","2907, NA","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03749850","BiomarkerKG1825741352"
"318","ATORVASTATIN","DB01076","60822","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","STAGE IIB-III TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03872388","BiomarkerKG156569843"
"319","IPILIMUMAB, NIVOLUMAB, TALIMOGENE LAHERPAREPVEC","DB06186,DB09035,DB13896","NA, NA, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","LOCALIZED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04185311","BiomarkerKG-179581873"
"320","IPILIMUMAB, NIVOLUMAB, TALIMOGENE LAHERPAREPVEC","DB06186,DB09035,DB13896","NA, NA, NA","ERBB2, ERS1","ENSG00000141736, NA","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","LOCALIZED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04185311","BiomarkerKG-1062210253"
"323","PEMBROLIZUMAB, CYCLOPHOSPHAMIDE, GX-I7","DB09037,DB00531,NA","NA, 2907, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","REFRACTORY OR RELAPSED TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03752723","BiomarkerKG2095042473"
"324","TRASTUZUMAB","DB00072","3001322","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","EARLY BREAST CANCER","MONDO_0007254","UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04109391","BiomarkerKG-1855863757"
"325","RUCAPARIB, SACITUZUMAB GOVITECAN","DB12332,DB12893","9931953, 91668186","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03992131","BiomarkerKG1193506727"
"327","PALBOCICLIB, LETROZOLE","DB09073,DB01006","11478676, 3902","ERBB2, ERS1, PGR, Ki67","ENSG00000141736, NA, ENSG00000082175, ENSG00000148773","Protein Expression, Protein expression, Protein expression, Protein Expression","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND KI67 PROTEIN EXPRESSION POSITIVE","BREAST CANCER","MONDO_0007254","UNK. UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04130152","BiomarkerKG-563823741"
"329","ATEZOLIZUMAB, G100","DB11595,NA","NA, 159968","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03915678","BiomarkerKG1689293800"
"333","TREMELIMUMAB, DURVALUMAB","DB11771,DB11714","NA, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","CTLA4, PDL1","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03982173","BiomarkerKG1323565151"
"334","CB-839, TALAZOPARIB","NA,DB11760","71577426, 135565082","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein expression, Protein expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","METASTATIC TRIPLE NEGATIVE BREAST CANCER","MONDO_0007254","UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03875313","BiomarkerKG3321966"
"335","IPATASERTIB, FULVESTRANT, LETROZOLE, PALBOCICLIB","DB11743,DB00947,DB01006,DB09073","24788740, 104741, 3902, 11478676","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","AKT, UNK, Aromatase, CDK4/CDK6","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03959891","BiomarkerKG1410798894"
"336","TAMOXIFEN CITRATE, LETROZOLE, EXEMESTANE","NA,DB01006,DB00990","2733525, 3902, 60198","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Positive, Positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND PGR PROTEIN EXPRESSION POSITIVE","INVASIVE DUCTAL BREAST CANCER (STAGES I-III)","EFO_0000186","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04129216","BiomarkerKG-37577398"
"341","PERTUZUMAB, TRASTUZUMAB, PACLITAXEL, DOXORUBICIN, CYCLOPHOSPHAMIDE, DOCETAXEL, CARBOPLATIN, PEGFILGRASTIM","DB06366,DB00072,DB01229,DB00997,DB00531,DB01248,DB00958,DB00019","NA, 3001322, 36314, 443939, 2907, 148124, 56840877, NA","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression&amplification, protein expression, protein expression","Positive, Negative/Positive, Negative/Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE/POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03329378","BiomarkerKG214156408"
"342","DURVALUMAB, OLAPARIB, AZD6738","DB11714,DB09074,NA","NA, 23725625, 54761306","ERBB2, ERS1, PGR","ENSG00000141736, NA, ENSG00000082175","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE","INVASIVE TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PDL1, PARP, ATR","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03740893","BiomarkerKG1059450097"
"343","NIVOLUMAB, NAB-PACLITAXEL, IPILIMUMAB","DB09035,NA,DB06186","NA, 36314, NA","ERBB2, ERS1","ENSG00000141736, NA","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE","METASTATIC BREAST CANCER","EFO_1000984","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04132817","BiomarkerKG-1378819185"
"345","FUTIBATINIB, FULVERSTRANT","DB15149,NA","71621331, NA","ERBB2, ERS1, PGR, FGFR2","ENSG00000141736, NA, ENSG00000082175, ENSG00000066468","Protein Expression, Protein Expression, Protein Expression, Protein Expression&Amplification","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND FGFR2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","FGFR, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04024436","BiomarkerKG-323468877"
"346","FUTIBATINIB","DB15149","71621331","ERBB2, ERS1, PGR, FGFR2","ENSG00000141736, NA, ENSG00000082175, ENSG00000066468","Protein Expression, Protein Expression, Protein Expression, Protein Expression&Amplification","Negative, Negative, Negative, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND/OR PGR PROTEIN EXPRESSION NEGATIVE AND FGFR2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","FGFR","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04024436","BiomarkerKG-1064188360"
"347","FUTIBATINIB, FULVERSTRANT","DB15149,NA","71621331, NA","ERBB2, ERS1, PGR, FGFR1","ENSG00000141736, NA, ENSG00000082175, ENSG00000077782","Protein Expression, Protein Expression, Protein Expression, Protein Expression&Amplification","Negative, Positive, Positive, Positive","AND, AND/OR, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION POSITIVE AND/OR PGR PROTEIN EXPRESSION POSITIVE AND FGFR1 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","LOCALLY ADVANCED BREAST CANCER","MONDO_0007254","FGFR, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT04024436","BiomarkerKG-1254885361"
"348","GEDATOLISIB, TALAZOPARIB","DB11896,DB11760","44516953, 135565082","ERBB2, ERS1, PGR, BRCA1, BRCA2","ENSG00000141736, NA, ENSG00000082175, ENSG00000012048, ENSG00000139618","Protein Expression, Protein expression, Protein expression, Mutation, Mutation","Negative, Negative, Negative, Negative, Negative","AND, AND, AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ERS1 PROTEIN EXPRESSION NEGATIVE AND PGR PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION NEGATIVE AND BRCA2 MUTATION NEGATIVE","UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PI3K/mTOR, PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03911973","BiomarkerKG-1702088471"
"349","GEDATOLISIB, TALAZOPARIB","DB11896,DB11760","44516953, 135565082","ERBB2, BRCA1, BRCA2","ENSG00000141736, ENSG00000012048, ENSG00000139618","Protein Expression, Mutation, Mutation","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 MUTATION POSITIVE AND/OR BRCA2 MUTATION POSITIVE","UNRESECTABLE TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","PI3K/mTOR, PARP","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03911973","BiomarkerKG535034914"
"350","NAB-PACLITAXEL, CARBOPLATIN, HERCEPTIN","NA,DB00958,NA","36314, 56840877, NA","ERBB2","ENSG00000141736","Protein Expression&amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","BREAST CANCER","MONDO_0007254","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03907800","BiomarkerKG716117938"
"351","NAB-PACLITAXEL, CARBOPLATIN, HERCEPTIN","NA,DB00958,NA","36314, 56840877, NA","ERBB2, BRCA1, BRCA2","ENSG00000141736, ENSG00000012048, ENSG00000139618","Protein Expression, Protein Expression, Protein Expression","Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND BRCA1 PROTEIN EXPRESSION NEGATIVE AND BRCA2 PROTEIN EXPRESSION NEGATIVE","TRIPLE NEGATIVE BREAST CANCER","EFO_0005537","UNK, UNK, UNK","pass","TVV","Breast_Cancer_Clinical_Trials_Annotated.xlsx","clinicaltrials.gov","NCT03907800","BiomarkerKG107230865"
"356","CYCLOPHOSPHAMIDE, CYTOKINE-BASED BIOLOGIC AGENT IRX-2, NIVOLUMAB","DB00531,NA,DB09035","2907, NA, NA","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","RECURRENT OR METASTATIC HEPATOCELLULAR CARCINOMA","EFO_0000702","UNK, UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03655002","BiomarkerKG2139946516"
"358","ANLOTINIB HYDROCHLORIDE",NA,"57380530","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","VEGFR, FGFR, PDGFR, CKIT","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT04213118","BiomarkerKG-1142743362"
"359","COLCHICINE","DB01394","6167","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA (IIIB-IV)","EFO_0000707","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT04264260","BiomarkerKG2027096547"
"370","PRAVASTATIN","DB00175","16759173","AFP","ENSG00000081051","Protein Expression","Positive/Negative",NA,"AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03219372","BiomarkerKG683286200"
"371","APATINIB","DB14765","45139106","VEGF, AFP","ENSG00000112715, ENSG00000081051","Protein Expression, Protein Expression","Positive, Positive","AND","VEGF PROTEIN EXPRESSION POSITIVE AND AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","VEGFR","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03511703","BiomarkerKG440468617"
"407","ATG-008",NA,"58298316","HBV","ENSG00000112773","missing","Positive",NA,"HBV MISSING POSITIVE","ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03591965","BiomarkerKG329189688"
"409","DERAZANTINIB","DB14889","46834118","FGFR2","ENSG00000066468","mutation/gene fusion/amplification","Positive",NA,"FGFR2 MUTATION/GENE FUSION/AMPLIFICATION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA, LOCALLY ADVANCED UNRESECTABLE OR METASTATIC INTRAHEPATIC CHOLANGIOCARCINOMA","EFO_0009260","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03230318","BiomarkerKG1352760165"
"411","RAMUCIRUMAB, MEDI4736","DB05578,NA","NA, NA","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02572687","BiomarkerKG1751026797"
"416","SORAFENIB","DB00398","406563","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03178656","BiomarkerKG-1685288106"
"434","BAVITUXIMAB, SORAFENIB","DB05136,DB00398","NA, 406563","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARINOMA","EFO_0009709","UNK/UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01264705","BiomarkerKG626426273"
"435","PD-0332991",NA,"5330286","RB","ENSG00000139687","Protein Expression","Positive",NA,"RB PROTEIN EXPRESSION POSITIVE","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","CDK4/CDK6","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01356628","BiomarkerKG-1504368928"
"437","LENALIDOMIDE","DB00480","216326","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01545804","BiomarkerKG-1815733615"
"438","BEVACIZUMAB, ERLOTINIB","DB00112,DB00530","NA, 176871","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED LIVER CANCER","MONDO_0002691","VEGF, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01180959","BiomarkerKG-61478009"
"440","AXITINIB","DB06626","6450551","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","METASTATIC HEPATOCELLULAR CARCINOMA","EFO_0000702","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01334112","BiomarkerKG1400964458"
"441","EVEROLIMUS, PASIREOTIDE","DB01590,DB06663","6442177, 9941444","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01488487","BiomarkerKG936726893"
"442","SORAFENIB, E7050","DB00398,NA","406563, 16118392","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HCC","EFO_0009709","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01271504","BiomarkerKG-595661003"
"443","ADI-PEG 20","DB06592",NA,"Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01287585","BiomarkerKG-1250742185"
"444","TYROSERLEUTIDE, MITOMYCIN, FLUOROURACIL","NA,DB00305,DB00544","10045387, 5746, 3385","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01489566","BiomarkerKG223828977"
"448","TS-1, OXALIPLATIN","NA,DB00526","5386, 5310940","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01429961","BiomarkerKG-1086386656"
"450","S-1, LEUCOVORIN","NA,DB00650","5462310, 135403647","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01533324","BiomarkerKG-1960843667"
"453","ETHIODIZED OIL, DOXORUBICIN","DB00965,DB00997","NA, 443939","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01966133","BiomarkerKG912675784"
"455","PRAVASTATIN, SORAFENIB","DB00175,DB00398","16759173, 406563","Absent","ENSG00000104313",NA,NA,NA,"ABSENT NA NA","ADVANCED HEPATOCARCINOMA","EFO_0009260","UNK, UNK","pass","ALV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01418729","BiomarkerKG-1583497180"
"458","SORAFENIB TOSYLATE, VORINOSTAT","NA,DB02546","406563, 5311","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260",NA,"pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT01075113","BiomarkerKG1436097858"
"503","ASLAN001",NA,"42642648","HER3","ENSG00000065361","Protein Expression","Positive",NA,"HER3 PROTEIN EXPRESSION POSITIVE","METASTATIC HEPATOCELLULAR CARCINOMA","EFO_0000702","EGFR/HER2/HER4","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03499626","BiomarkerKG1088441413"
"542","APATINIB, SHR-1210","DB14765,NA","45139106, NA","AFP","ENSG00000081051","Protein Expression","neagative",NA,"AFP PROTEIN EXPRESSION NEAGATIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","VEGFR2, PD1","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03722875","BiomarkerKG76141553"
"546","RAMUCIRUMAB","DB05578",NA,"AFP","ENSG00000081051","Protein expression","positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02435433","BiomarkerKG-2114961874"
"547","GALUNISERTIB, NIVOLUMAB","DB11911,DB09035","10090485, NA","AFP","ENSG00000081051","Protein expression","positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","RECURRENT HEPATOCELLULAR CARCINOMA","EFO_0000707","Growth Factor-beta Receptor I Kinase, PD1","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02423343","BiomarkerKG1273878690"
"550","FISOGATINIB",NA,"91885617","FGF19","ENSG00000162344","protein expression","positive/negative",NA,"FGF19 PROTEIN EXPRESSION POSITIVE/NEGATIVE","HEPATOCELLULAR CARCINOMA","EFO_0000182","UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02508467","BiomarkerKG901214447"
"558","ERDAFITINIB","DB12147","67462786","FGF19","ENSG00000162344","Protein expression&amplification","positive",NA,"FGF19 PROTEIN EXPRESSION&AMPLIFICATION POSITIVE","ADVANCED HEPATOCELLULAR CARCINOMA","EFO_0009260","UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02421185","BiomarkerKG320452314"
"559","OXALIPLATIN, 5-FLUOROURACIL","DB00526,DB00544","5310940, 3385","AFP","ENSG00000081051","Protein expression","positve/negative",NA,"AFP PROTEIN EXPRESSION POSITVE/NEGATIVE","EARLY STAGE HEPATOCELLULAR CARCINOMA","EFO_0001663","UNK, UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02767375","BiomarkerKG-1047036954"
"575","APATINIB","DB14765","45139106","AFP","ENSG00000081051","Protein expression","positive/negative",NA,"AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED HEPATOCELLULAR CANCER","EFO_0000311","UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT03046979","BiomarkerKG1160551452"
"576","PEMBROLIZUMAB","DB09037",NA,"AFP","ENSG00000081051","Protein expression","positive/negative",NA,"AFP PROTEIN EXPRESSION POSITIVE/NEGATIVE","ADVANCED HEPATOCELLULAR CANCER","EFO_0000311","UNK","pass","TVV","Liver_Clinical_Trials.xlsx","clinicaltrials.gov","NCT02658019","BiomarkerKG1309435194"
"583","BEVACIZUMAB","DB00112",NA,"
VEGF-A
","ENSG00000112715","
protein expression
",NA,NA,"VEGF-A PROTEIN EXPRESSION NA","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-v4-030920-30-revised-2.xlsx","PubMed","31564802","BiomarkerKG286515678"
"585",NA,NA,"56956252","miRNA","ENSG00000037897","gene expression",NA,NA,"MIRNA GENE EXPRESSION NA","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-v4-030920-30-revised-2.xlsx","PubMed","31549595","BiomarkerKG1449458760"
"586","CABOZANTINIB, TRASTUZUMAB","DB08875,DB00072","25102846, 3001322","VEGFR 2","ENSG00000165197","protein expression",NA,NA,"VEGFR 2 PROTEIN EXPRESSION NA","BREAST CANCER BRAIN METASTASES (BCBM)","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-v4-030920-30-revised-2.xlsx","PubMed","31541381","BiomarkerKG-338123991"
"589",NA,NA,"56956252","PIK3CA","ENSG00000121879","mutation",NA,NA,"PIK3CA MUTATION NA","BREAST CANCER PRECLINICAL MODELS.","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-v4-030920-30-revised-2.xlsx","PubMed","31534012","BiomarkerKG-1006830416"
"590",NA,NA,"56956252","
SNP","ENSG00000145901","
polymorphism",NA,NA,"SNP POLYMORPHISM NA","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-v4-030920-30-revised-2.xlsx","PubMed","31519601","BiomarkerKG91698316"
"598",NA,NA,"56956252","SLCO1B3","ENSG00000111700","mutation",NA,NA,"SLCO1B3 MUTATION NA","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-v4-030920-30-revised-2.xlsx","PubMed","31434449","BiomarkerKG869601495"
"603",NA,NA,"56956252","PD-1","ENSG00000265681","protein expression",NA,NA,"PD-1 PROTEIN EXPRESSION NA","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-v4-030920-30-revised-2.xlsx","PubMed","31357142","BiomarkerKG-1299119812"
"635","BAY 1125976",NA,"70817911","AKT","ENSG00000166971","mutation","positive",NA,"AKT MUTATION POSITIVE","BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-v4-031120-40-v2.xlsx","PubMed","31835495","BiomarkerKG-1256644265"
"638","NAPABUCASIN, TAMOXIFEN","DB12155,DB00675","10331844, 2733526","ESR1","ENSG00000091831","protein expression","positive",NA,"ESR1 PROTEIN EXPRESSION POSITIVE","ESTROGEN RECEPTOR-POSITIVE (ER+) BREAST CANCER","MONDO_0007254",NA,"pass","Ben","Breast-Cancer-Drug_biomarkers-pubmed-v4-031120-40-v2.xlsx","PubMed","31760402","BiomarkerKG-2145370017"
